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Neuroblastoma is a childhood tumour characterized by genetic
heterogeneity and non-random chromosome defects associated
with rapid tumour progression. MYCN gene amplification (Seeger
et al, 1985), deletion of chromosome 1p36 (Caron et al, 1996)
and gain of 17q (Bown et al, 1999) are associated with a poor
prognosis. Over the last few years the Comparative Genomic
Hybridization (CGH) technique has been performed with success
to detect genomic imbalances in both frozen and paraffin-
embedded tumour tissue. In neuroblastoma CGH has revealed the
presence of multiple genetic defects, including losses of chromo-
somes 4p, 9p, 11q, 14q and gains of 17q, 4q and 6p (Brinkschmidt
et al, 1997; Lastowska et al, 1997; Plantaz et al, 1997; Vande-
sompele et al, 1998).
The outcome of patients with localized neuroblastoma is gener-
ally good, but patients with metastatic disease have a very poor
survival rate despite the newest therapies. The better outcome of
the former group probably depends on the different genetic and
molecular alterations present in their tumours. Furthermore, a
subset of patients with advanced disease has a longer survival rate,
showing complete remission or a stable disease. We hypothesized
that the tumours of this subset have distinct features, allowing
them to survive.
We examined 22 samples of neuroblastoma by CGH to investi-
gate the genetic aspects of the tumours of patients with advanced
neuroblastoma and long vs short-term survival. According to our
results the tumours of patients who died from disease progression
show a significantly higher number of structural chromosome
abnormalities and gain of 17q, in comparison to the numerical
aberrations and 17 trisomy that characterize the tumour of long-
term survivors. The particular genetic pattern observed in the latter
may be useful for the prediction of a better outcome for patients
with advanced neuroblastoma.
MATERIALS AND METHODS
Patients
22 tumour cell samples collected at time of surgery before any
treatment and stored in the Italian Neuroblastoma Tissue Bank
were used for CGH analysis. All patients were over 1 year old at
time of diagnosis, and 21 out 22 had an abdominal primary.
Patients were staged according to INSS (Brodeur et al, 1993) and
tumours classified according to the Shimada criteria (1984).
Patients were treated following the current protocols by the Italian
Cooperative Neuroblastoma Study Group. The samples included
in the study derived from 6 patients at stage 3 and 16 at stage 4.
Patients were selected according to their status at time of the
analysis (Table 1). All patients of group A were alive with at least
a 3-year follow up. In group B, all except patient 21 have a shorter
survival.
Tumour samples
High molecular weight DNA was isolated from primary tumours
or bone marrow aspirates at time of diagnosis and from leukocytes
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more than 90% in all samples.
Comparative genomic hybridization
CGH was performed as described by Kallioniemi et al (1992).
Metaphases were prepared from phytohaemagglutinin-stimulated
peripheral blood lymphocytes of normal healthy male donors
according to standard procedures. Digital images were collected
through a computer-controlled Nikon E800 fluorescence micro-
scope (Nikon, Italy) connected to a Cytovision Workstation
(Applied Imaging, Santa Clara, CA). Three-colour images repre-
senting tumour (green), reference DNA (red) and DAPl counter-
stain (blue) were captured for each metaphase and analysed as
separate grey-scale images. Chromosomes were identified by
DAPI; green and red fluorescence intensities were then scored
along the vertical medial axis of each chromosome. For evaluation
of CGH data average ratio profiles with fixed limits at 1.25 and
0.75 (standard deviation limits: 95%) and individual ratio profiles
were analysed. Chromosomes X and Y were excluded from the
analysis. CGH controls were performed by matching two normal
donors’ purified DNAs.
Fluorescence in situ hybridization (FISH) and loss of
heterozygosity (LOH) for chromosome 1p36
Chromosome 1p deletion was evaluated by two-colour FISH on
tumour cell interphase nuclei as previously described (Lo Cunsolo
et al, 1999). Probes pI-79 (locus D1Z2 at 1pter) and QC (chromo-
some 1 centromere) were used. LOH for 1p36 was studied by the
PCR method using the primer sets for D1S80 and D1S76 loci
according to Peter et al (1992).
MYCN gene amplification
MYCN amplification was determined by Southern blot as previ-
ously described (Tonini et al, 1997) and, when possible, by double
colour FISH using the NB-19-21 and D2Z (Oncor, Heidelberg,
Germany) chromosome 2 centromeric probes.
Statistic analysis
c2 test was employed to compare gains of whole chromosomes
in tumours of living and dead patients. The differences in the
frequency of chromosome abnormality found in tumour samples
were tested by Fisher’s exact test.
RESULTS
We studied by CGH 22 tumour samples of patients with advanced
neuroblastoma, including long-term survival patients (group A)
and patients who died from disease progression (group B). The
median follow up was 60 (48–72) months for group A and 27
(1–53) months for group B. Six out of eight patients of group A, up
until now, are in complete remission; the remaining 2 are alive
with stable disease and do not require further treatment. All
patients of group B (except case no. 14) died from disease progres-
sion. Patient no. 14 died from toxicity (Table 1).
We detected a total of 226 chromosome imbalances, 110 in
group A and 116 in group B. Group A shows a higher frequency of
numerical aberrations in term of gains and losses (54% vs 43%).
Whole chromosome gains were more prevalent in group A (37%)
compared to group B (27%) (c2 = 2.89; P < 0.09). Group A shows
35% of structural abnormalities (gene amplification excluded)
compared with 43% observed in group B (c2 = 1.38; P < 0.24).
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Table 1 Clinical data and follow up of 22 patients with advanced neuroblastomas, MYCN gene amplification, chromosome 1 and 17 status in tumour samples
Group A
Case Stage Age at Follow upa Chr 2 by CGH/MYCN Chr 1 by CGH/1p Chr. 17 by
diagnosisa by FISH & SB by FISH or LOH CGH
1 3 22 72,CR normal/normal +1/n.d. +17
2 4 22 60,CR gain/normal normal/n.d. +17
3 4 27 72,CR normal/normal +1/n.d. normal
4 4 31 48,CR normal/normal +1/normal +17
5 4 32 60,CR gain/ampl 1q loss/n.d. +17q
6 4 79 60,AWD gain/normal +1/normal +17
7 4 86 48,CR normal/normal 1q loss/normal +17
8 4 101 48,AWD normal/normal +1/n.d. +17
Group B
9 3 15 13,DWD gain/normal 1p loss/deleted +17q
10 3 23 20,DWD gain/ampl 1p loss/deleted normal
11 3 28 13,DWD gain/ampl normal/deleted normal
12 3 50 18,DWD normal/normal normal/normal +17q
13 3 52 6,DWD normal/normal normal/normal +17q
14 4 12 1,TOX gain/normal normal/normal +17q
15 4 26 9,DWD normal/normal normal/normal +17q
16 4 26 17,DWD gain/ampl 1q gain/deleted +17q
17 4 29 30,DWD normal/normal normal/normal +17
18 4 32 11,DWD normal/normal normal/normal 17qdel
19 4 49 20,DWD normal/normal +1/normal +17q
20 4 58 1,DWD gain/normal 1p loss/deleted +17q
21 4 132 53,DWD normal/normal 1p loss/deleted normal
22 4 138 9,DWD normal/ampl normal/deleted normal
a Age at diagnosis and follow up are expressed in months, CR: complete remission; AWD: alive with disease; DWD: died with disease, TOX: died from toxicity;
n.d.: not done; n.i.: not informative; SB: Southern blotResults of chromosome imbalances are reported in the ideogram in
Figure 1.
Whole chromosome gains and losses
In group A extra copies of chromosomes 1, 7, 17 and 19 were
observed in 5/8, 4/8, 6/8 and 7/8 cases (63%, 50%, 75% and 88%
respectively). In group B additional chromosomes 1, 7, 17 and 19
were present in 2/14, 1/14, 1/14 and 6/14 cases (14%, 7%, 7% and
43%) (Figure 1). A statistically significant difference for chromo-
some gains 1 (P < 0.03), 7 (P < 0.04), 19 (P < 0.05) and 17
(P < 0.002) stood out between group A and B tumors. These
differences are shown in Figures 2A, B.
Partial chromosome gains and losses
Additional chromosome 17q material was found in 1/8 (13%)
samples of group A and 8/14 (57%) samples of group B. In the
case of group A and in 3/8 cases of group B gain of 17q includes
the region 17q11.2®qter whereas 5/8 cases of group B shows gain
from 17q21 to qter (Figure 1). Chromosome 17q was significantly
gained in the tumours of patients who died from disease progres-
sion (P < 0.05). The comparison between chromosome 17 and 17q
gains in living and dead patients is presented in Figure 2B.
The 2p23–24 chromosome region was amplified in 9 tumours.
Three cases belonged to group A patients and 6 to group B ones.
Since this region includes the locus for MYCN gene, we performed
Southern blot and/or FISH analysis to verify the presence of
MYCN amplification. Four tumours (cases 5, 10, 11, and 16)
showed gain of 2p24 region and MYCN amplification; in cases 2,
6, 9, 14 and 20 an excess of green signal at 2p24 did not corre-
spond to MYCN amplification. Case 22 did not show imbalance at
this region, but MYCN amplification was present, as detected by
Southern blot.
Loss of chromosome 1p was detected in 7 tumours of group B
but not in those of group A (Figure 1). Four cases of group B (9,
10, 20, 21) showed chromosome 1p deletion which was readily
evident by CGH, whereas three additional cases (11, 16, 22) were
detected by FISH and not by CGH (Table 1). This discrepancy
likely reflects the intrinsic limitations of CGH, which can only
detect deletions larger than 10 Mb in size (Van Gele et al, 1997;
Van Roy et al, 1997). When constitutional DNA was available
from patients, FISH results were confirmed by LOH.
Loss of chromosome 9p was found in 4/8 (50%) cases of group
A and 2/14 (14%) cases of group B. Chromosome 11q was lost
in 4/8 (50%) tumours of group A and 2/14 (14%) tumours of
group B.
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Figure 1 Ideogram of DNA imbalances in 22 samples of neuroblastoma tumours of group A (top panel) and group B (bottom panel) patients (see Table 1 for
details). Lines on the left side of the ideograms indicate under-representations, lines and bars on the right side indicate over-representation and gene
amplification respectivelyDISCUSSION
In the present report we show that tumours of surviving patients
with advanced neuroblastoma are frequently characterized by
numerical chromosome aberrations, whereas tumours of children
who died from disease progression have more structural abnormal-
ities, including gain of 17q. Particularly, we observed that gain of
17q was present in 8/14 (57%) tumours of group B and only 1/8
(13%) tumours of group A, which suggests that this chromosome
plays an important role in tumour growth. On a total of 9 cases that
show 17q gain, 4 cases belonging to group B display a gain that
includes the region 17q11.2®qter and 5 the region q21®qter.
The latter region has been frequently involved in the unbalanced
translocation t(1p;17q) found in neuroblastoma cell lines
(Lastowska et al, 1998). Indeed, in both neuroblastoma cell lines
and tumours it has been shown that chromosome 17q can translo-
cate to several different chromosomes, thus leading to remarkably
complex translocations (Meddeb et al, 1996; Van Roy et al; 1997;
Lastowska et al, 1998).
In the present work, gains of an entire chromosome 17 were
detected in 75% of surviving children’s tumours. We hypothesize
that the additional copy of chromosome 17 derives from an
abnormal mitosis or from the non-disjunction of chromosomes
during the mitotic process. In either cases the additional copy of 17
should not alter the function of a specific gene enclosed on this
chromosome. Our data suggest that the extra copy of chromosome
17 does not contribute to tumour aggressiveness. Conversely, the
presence of +17q in group B appeared to be associated with a poor
outcome and was not significantly associated with MYCN amplifi-
cation or 1p deletion. Patient no. 5 (group A) represents an excep-
tion, since he is still alive and in complete remission, although his
tumour shows unfavourable markers such as MYCN amplification
and +17q. Bown et al (1999) have observed a strong association
between MYCN amplification, chromosome 1p deletion and gain
of 17q. Probably, the discrepancy between Bown’s data and ours is
caused by the limited number of samples that we analysed. At any
rate, our results, together with the data reported by Bown et al
(1999), further support a role of chromosome 17q in the develop-
ment and progression of neuroblastoma. Finally, our analysis
clearly defines a subset of longer-term survival patients whose
tumours do not show gross 17q abnormality. This finding may
contribute to identifying patients with advanced disease and a
more favourable outcome.
A gain at the 2p24 was found in 5 tumours by CGH analysis
without a MYCN gene amplification. In this region is mapped the
DDXI gene; DDXI is far from MYCN gene of 400 kbp and has
been found co-amplified in human neuroblastoma cell lines and
tumours (Amler et al, 1996; George et al, 1997). Although, DDXI
has been found, until now, co-amplified with MYCN (George et al,
1997) we may argue that gain at 2p24 region could be associated
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Figure 1 continued.with the presence of DDXI gene extracopies or other amplifed
DNA sequences (Wimmer et al, 1999).
Losses of 9p were detected in 50% of the tumours of group A
and in 14% of group B, which confirms previous observations on
the defect of this chromosome in advanced neuroblastoma (Takita
et al, 1995; Iolascon et al, 1998). However, a higher frequency of
9p deletion in the tumours of group A suggests that p16INK4A gene,
which usually shows allelic loss in 9p-deleted neuroblastomas, is
not essential to tumour progression but participate only in the
deregulation of cell cycle.
Hence, tumours of patients with advanced neuroblastoma seem
to be characterized by non-random primary chromosome alter-
ations such as MYCN amplification, 1p deletion and gain of 17q,
along with secondary non-random abnormalities such as del(11q),
del(9p) and gain of 12q. The role of chromosome 18q was already
reported by Takita et al (1995), but in our cases loss of 18q was
found both in group A and B. Gain of an entire chromosome 19
was observed in both groups. No rearrangements of this chromo-
some were detected, so its role in tumour progression still remains
unclear.
Finally, it is interesting to note that the genetic features of the
tumours of surviving patients are very similar to those of children
with localized disease retaining additional copies of several
chromosomes (Brinkschmidt et al, 1997; Plantaz et al, 1997;
Vandesompele et al, 1998). This suggests that an extra copy of an
entire chromosome in both localized and disseminated neuro-
blastoma characterizes a less aggressive tumour phenotype.
Genome analysis by CGH may be considered a suitable tool to
screen primary tumours at the onset of the disease in order to
identify high-risk patients with advanced neuroblastoma.
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Figure 2 (A) distribution of gains of whole chromosomes 1, 7 and 19 in
tumours of long (group A) and short-term (group B) survival patients.
Tumours of survived patients significantly gain an extra copy of 1 (P < 0.03),
7 (P < 0.04) and 19 (P < 0.05). (B) Distribution of gains of chromosome 17
and 17q in tumours of long (group A) and short-term (group B) survival
patients. Tumours of survived patients significantly gain a whole chromosome
17 (P < 0.002), whereas tumours of patients who died from disease
progression gain 17q (P < 0.05)1300 C Lo Cunsolo et al
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